HiberCell and Merck to Evaluate HC-7366 + WELIREG (belzutifan) in Ph 1b Study of ccRCC Patients
“We are excited to collaborate with Merck to evaluate HC-7366 in combination with belzutifan,” said Jonathan Lanfear, President & CEO of HiberCell. “We are also excited to announce that one of the scientific leaders within the RCC space, Dr. Robert Motzer, will be our lead PI for this important trial. We expect this study to build on what we have demonstrated preclinically, showing that the combination of these two therapies has the potential to significantly broaden and deepen patient responses relative to belzutifan alone. This trial will also build on the data from our ongoing Ph1a/1b monotherapy studies for HC-7366 in solid tumors. We are eager to pursue this investigational combination in a setting where additional treatment options for patients are needed.”
Share:
More News
“Fast Track designation in lung cancer represents an important milestone for TRE-515 and further validates our strategy of combining dCK inhibition with targeted cancer therapies,” said Dr. Ken Schultz, Trethera Chairman and CEO. “KRAS G12C inhibitors have transformed the NSCLC treatment landscape, but resistance and incomplete responses remain major challenges.
“AvenCell has built a differentiated cell therapy platform that brings together CRISPR-engineered allogeneic CAR-T technology with a unique switchable CAR approach designed to provide greater control over CAR-T activity,” said Todd Davis, CEO of Ligand. “We believe the combination of these technologies, together with the encouraging clinical data generated to
“Advanced gastric cancer is characterized by substantial biological and clinical heterogeneity. Previous studies have shown that the magnitude of benefit from PD-1 inhibitor therapy is closely associated with PD-L1 expression, and that there remains room to further improve outcomes, particularly in patients with low PD-L1 expression. How to broaden the
“The evERA results represent an important step forward for people with ER-positive advanced breast cancer and underscore the potential for giredestrant to help address the challenge of disease progression in this setting,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “Together with the